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Abstract
Background: Experimental studies showed that 25-hydroxy-vitamin D [25(OH)D] deficiency (defined as 25-hydroxy-
vitamin D < 15 ng/ml) has been associated with CKD progression. Patients with IgA nephropathy have an exceptionally
high rate of severe 25(OH)D deficiency; however, it is not known whether this deficiency is a risk factor for progression
of IgA nephropathy. We conducted this study to investigate the relationship between the plasma level of 25(OH)D and
certain clinical parameters and renal histologic lesions in the patients with IgA nephropathy, and to evaluate whether
the 25(OH)D level could be a good prognostic marker for IgA nephropathy progression.
Methods: A total of 105 patients with biopsy-proven IgA nephropathy were enrolled between 2012 and 2015. The
circulating concentration of 25(OH)D was determined using serum samples collected at the time of biopsy. The
primary clinical endpoint was the decline of estimated glomerular filtration rate (eGFR; a 30 % or more decline
compared to the baseline).
Results: Mean eGFR decreased and proteinuria worsened proportionally as circulating 25(OH)D decreased (P < 0.05).
The 25(OH)D deficiency was correlated with a higher tubulointerstitial score by the Oxford classification (P = 0.008). The
risk for reaching the primary endpoint was significantly higher in the patients with a 25(OH)D deficiency compared to
those with a higher level of 25(OH)D (P = 0.001). As evaluated using the Cox proportional hazards model, 25(OH)D
deficiency was found to be an independent risk factor for renal progression [HR 5.99, 95 % confidence intervals (CIs) 1.
59–22.54, P = 0.008].
Conclusion: A 25(OH)D deficiency at baseline is significantly correlated with poorer clinical outcomes and more sever
renal pathological features, and low levels of 25(OH)D at baseline were strongly associated with increased risk of renal
progression in IgAN.
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Background
IgA nephropathy (IgAN) is the most common form of
glomerulonephritis worldwide [1], especially in Asia, and
represents one of the main causes of the end-stage renal
diseases (ESRD) [2]. Male gender, early-onset, absence of
macroscopic hematuria, persistent microscopic hematuria,
hypertension, proteinuria, presence of renal dysfunction at
the time of diagnosis, and certain histological features of
renal lesions have been identified as important risk factors
for its progression[3–6].
Recent observations suggest that low vitamin D levels,
measured as 25-hydroxyvitamin D [25(OH)D] is signifi-
cantly associated with a more severe decrease in estimated
glomerular filtration rate (GFR) in patients with chronic
kidney diseases (CKD) [7, 8]. A series of studies have also
suggested a role of vitamin D [9] deficiency (defined as 25-
hydroxy-vitamin D < 15 ng/ml) [10] in the short-life ex-
pectancy of CKD [11–13]. Bienaim’ et al. also reported that
patients with lower serum total 25(OH)D concentrations
at 3 months after transplantation exhibited lower kidney
allograft function at 1 year after transplantation and had
higher risk of the progression of interstitial fibrosis and
tubular atrophy. [14] Furthermore, among patients with
wide range of renal dysfunctions including ESRD, vitamin
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D deficiency showed the associations with vascular calcifi-
cation, vascular endothelial function, cardiovascular events,
and cardiovascular mortality. In the Third National Health
and Nutrition Examination Survey (NHANES III) cohort,
individuals with 25 (OH) vitamin D levels < 15 ng/ml had a
higher risk for all-cause mortality despite adjustments for
CKD stage and for potential confounders. [15] Therefore,
low vitamin D level is considered as a candidate novel risk
factor for poor outcome of renal disease. Experimental data
have indicated that vitamin D analogues mediate a de-
crease in albuminuria and slow the progression of kidney
injury in several animal models of kidney disease [16, 17].
Moreover, a randomized trial by Liu and colleagues [18]
has demonstrated that oral calcitriol results in decrease in
proteinuria in IgA nephropathy patients confirming earlier
results of Szeto et al. [19]. Experimental studies have re-
vealed that VD insufficiency upregulates the renin-
angiotensin system [20, 21] and the NF-κB pathway [22],
decreases the nitric oxide synthase transcription in vascular
endothelial cells [23–25], increases inflammation and oxi-
dative stress [26, 27], and therefore may be a risk factor for
progression of kidney diseases. However, to date there have
been few studies exploring the relationship between the
25(OH)D level and the progression of IgAN, we therefore
studied this aspect.
Methods
Patients and serum samples
A total of 105 patients with newly diagnosed, biopsy-
proven primary IgAN were recruited from The First Affili-
ated Hospital of Guangxi Medical University between
2012 and 2015. IgAN was diagnosed with mesangial depo-
sitions of IgA under immunofluorescence microscope and
with electron-dense deposits in the mesangium under
electron microscope. Blood samples were collected before
initial VD treatment at the time of kidney biopsy.
Basic data and study endpoint
Patient demographics as well as conventional clinical pa-
rameters including age, gender, body mass index (BMI),
blood pressure (BP), blood chemistry and daily proteinuria
were collected at the time of kidney biopsy. Blood chemis-
try tests included serum creatinine, albumin, uric acid, total
cholesterol and IgA. Estimated glomerular filtration rate
(eGFR) was calculated using the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) equation [28]. Con-
secutive changes in renal function and the daily proteinuria
were recorded during the follow-up period. Primary end-
point was defined as a decline of 30 % or more in eGFR
compared with the baseline. Medication history was re-
corded, including the use of renin-angiotensin system
(RAS) blockers such as angiotensin-converting enzyme in-
hibitors and angiotensin II receptor blockers, and immuno-
suppressors (IS) within 6 months of kidney biopsy and
during the follow-up period. Kidney biopsy was performed
to those patients with uncontrolled proteinuria or uncon-
trolled hypertension in spite of the use of RAS blockers.
However, according to the clinical judgment of the nephrol-
ogists, it would often be performed regardless of the effi-
cacy of RAS blockers. The patients who had a persistant
proteinuria greater than 1 g after the treatment of RAS
blocker or showed impaired renal function usually received
immunosuppressive treatment for 2-4 weeks after the
kidney biopsy. Steroid medicines were the mainstay of the
treatment. None of the participants had received IS
treatment before a renal histological confirmation.
Renal histopathology
All kidney tissue specimens were obtained by percutan-
eous kidney biopsy, and examined using light micro-
scope, immunofluorescent, and electron microscope. All
histological slides were evaluated by an experienced
renal pathologist. The four pathologic variables of the
Oxford classification, which was used in this study, were
scored as follows: mesangial score ≤0.5 (M0) or >0.5
(M1), absence (S0) or presence (S1) of segmental glo-
merulosclerosis, absence (E0) or presence (E1) of endo-
capillary hypercellularity, and tubular atrophy/interstitial
fibrosis that was graded as T0 (≤25 %), T1 (26–50 %) or
T2 (>50 %) [29].
Measurement of the 25-hydroxyvitamin D
Serum 25(OH)D was measured using electrochemilumi-
nescent immunoassay (ECLIA) with a Roche Elecsys
10100/201 system (Roche Diagnosis Elecsys) according to
the manufacturer’s protocol. All measurements were
performed in a blind manner and in duplicate. Vitamin D
deficiency is defined as 25-hydroxy-vitamin D < 15 ng/ml.
Statistical analyses
Descriptive data were analyzed for all variables. For con-
tinuous variables, results were presented as mean ± SD.
Variables were compared using one-way analysis of vari-
ance (ANOVA) and unpaired Student’s t-test for normally
distributed variables whereas Kruskal-Wallis Test was used
for non-normally distributed variables. Categorical variables
were recorded as frequency counts, and intergroup com-
parisons were analyzed using a chi-squared test. Event free
survival curves were derived from the Kaplan-Meier
method and differences between the two curves were tested
using the logrank test. The model of the Cox proportional
hazards was used to identify independent predictors for the
development of the primary endpoint. A correlation ana-
lysis was conducted in order to avoid multi-collinearity;
only one variable in highly correlated variable sets was se-
lected for multivariate analysis. Statistically significant cov-
ariables from univariate analysis and clinically important
covariables were included in the final multivariate Cox
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proportional hazard regression analysis, and backward
elimination and stepwise selection approaches were con-
ducted. A P < 0.05 is considered statistical significance. Data
analysis was performed using the SPSS for Windows,
version 12.0 (SPSS, Chicago, IL, USA).
Results
Basic clinical information of the participants
Table 1 shows the clinical characteristics of our study
population (n = 105) at the time of kidney biopsy. The me-
dian age was 34 years old, and 54.3 % of the participants
were men. Average level of the systolic BP, proteinuria,
and baseline eGFR were 131 mmHg, 2.04 g/24 h, and
75.46 mL/min/1.73 m2, respectively. One hundred and
one patients (96.2 %) had 25 (OH) vitamin D levels <
30 ng/ml, and fifty-one patients (48.6.5 %) had 25 (OH)
vitamin D < 15 ng/ml, which are the thresholds for 25
(OH) vitamin D insufficiency and deficiency, respectively.
By CDK stage, the proportions of patients with 25(OH)D
<15 ng/ml were:55 % (22 of 40) at stage 1,42.9 % (12 of
28) at stage 2,61.9 % (13 of 21) at stage 3,83.3 % (5 of 6) at
stage 4, and 90 % (9 of 10) at stage 5(shown as Table 2). A
total of 83 (79 %) patients were treated with RAS blockers
at the time of the kidney biopsy and 38 (36.2 %) patients
received immunosuppressive therapy within 2–4 weeks
after the kidney biopsy.
The correlation between clinical parameters and 25(OH)D
To identify the relationship between the serum level of
25(OH)D and several clinical parameters, we dichotomized
the patients, based on their serum concentration of
25(OH)D, into two groups: levels of 25(OH)D < 15 ng/ml
vs 15 ng/ml or greater. Compared with those showing a
higher 25(OH)D level, those with a 25(OH)D deficiency
were significantly associated with a lower eGFR and a
higher proteinuria level (Table 2). Age, BMI and serum IgA
level were not correlated with the 25(OH)D concentration.
Stepwise increases in the uric acid level and BP but a de-
crease in the serum albumin level were also associated with
the 25(OH)D level. These correlations were observed as
well when the 25(OH)D level was used as continuous vari-
ables (Table 3 and Fig. 1). There was a significant positive
correlation between the 25(OH)D level and the eGFR (r =
0.196, P < 0.05). Proteinuria was inversely correlated with
the 25(OH)D level (r = -0.553, P < 0.01). We also conducted
Table 1 Baseline characteristics of the study group with IgAN
Total (n = 105)
Age (year) 34.73 ± 12.19
Male (n/%) 57(54.3 %)
Smoker (n/%) 32(30.5 %)
Body mass index (kg/m2) 23.2 ± 3.18
Systolic blood pressure (mmHg) 131.21 ± 23.43
Diastolic blood pressure (mmHg) 81.57 ± 16.84
Microscopic hematuria (n/%) 67 (63.8 %)
Proteinuria(g/24 h) 2.04 ± 1.09
eGFR (mL/min/1.73 m2) 75.45 ± 39.18
Serum albumin (mg/dL) 33.88 ± 7.91
Serum total cholesterol (mg/dL) 5.76 ± 2.09
Serum IgA (mg/dL) 2.97 ± 1.92
Uric acid (mg/dL) 404.81 ± 123.59
Medical treatment (n/%)
RAS blockers 83 (79 %)
Immunosuppressant 38 (36.2 %)
Data are presented as mean ± SD. eGFR, estimated glomerular filtration rate;
IgAN, IgA nephropathy; RAS, renin-angiotensin system
Table 2 The correlation between clinical parameters and
25(OH)D level at the time of kidney biopsy
Variables Serum 25-hydroxyvitamin (ng/mL) P-value
≥15 ng/mL <15 ng/mL
Age (years) 36.19 ± 10.86 32.87 ± 13.62 0.18
Body mass index (kg/m2) 23.05 ± 2.86 23.39 ± 3.57 0.59
Systolic blood pressure
(mmHg)
123.95 ± 17.26 140.52 ± 26.96 0.001
Diastolic blood pressure
(mmHg)
76.66 ± 14.47 87.87 ± 17.70 0.001
Proteinuria(g/24 h) 1.23 ± 1.27 3.07 ± 2.06 <0.001
eGFR (mL/min/1.73 m2) 83.42 ± 32.64 65.24 ± 44.56 0.023
CKD stage 1(n/%) 18 (45 %) 22 (55 %) 0.069
CKD stage 2(n/%) 16 (57.1 %) 12 (42.9 %)
CKD stage 3(n/%) 8 (38.1 %) 13 (61.9 %)
CKD stage 4(n/%) 1 (16.7 %) 5 (83.3 %)
CKD stage 5(n/%) 1 (10 %) 9 (90 %)
Serum albumin (mg/dL) 38.08 ± 5.02 28.50 ± 7.72 <0.001
Serum total cholesterol
(mg/dL)
5.14 ± 1.21 6.57 ± 2.64 <0.001
Serum IgA (mg/dL) 3.15 ± 2.24 2.73 ± 1.38 0.27
Uric acid (mg/dL) 374.31 ± 112.68 443.93 ± 127.11 0.004
eGFR, estimated glomerular filtration rate
Table 3 Spearman correlation coefficients between various
clinical parameters in IgAN patients
proteinuria 25(OH)D SBP ALB UA
eGFR −0.377** 0.196* −0.656** 0.155 −0.513**
proteinuria 1 −0.553** 0.464** −0.564** 0.219*
25(OH)D 1 −0.316** 0.665** −0.140
SBP 1 −0.272** 0.302***
ALB 1 −0.065
UA 1
eGFR, estimated glomerularfiltration rate, SBP, systolic blood pressure, ALB
albumin, UA uric acid
*P < 0.05, **P < 0.01, ***P < 0.001
Li et al. BMC Nephrology  (2016) 17:164 Page 3 of 8
a correlation analysis between serum phosphorus, calcium,
and PTH levels with 25(OH)D level (result shown in
Additional file 1).
Relationship between histologic features and the plasma
25(OH)D
We examined the association between the plasma
25(OH)D level at the time of initial diagnosis and the sever-
ity of histologic lesions, and found that the plasma
25(OH)D level was associated with the percentage of
interstitial fibrosis/tubular atrophy. A lower plasma
25(OH)D level indicated a higher tubulointerstitial score
with the aforementioned Oxford classification (P = 0.008;
Table 4).
The impact of circulating 25(OH)D on clinical outcome
A total of 28 (26.7 %) patients reached the primary end-
point (renal progression; eGFR declined by 30 % or more
compared with the baseline level) during a median follow-
up period of 13 months. The primary endpoint was reached
Fig. 1 The 25(OH)D level is correlated negatively with eGFR (a) and positively with proteinuria (b), respectively, at the time of kidney biopsy
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by 24 patients with deficiency (39.3 %) and 4 patients with-
out (9.1 %). Time-to-event analysis showed that those pa-
tients with a 25(OH)D deficiency showed a significantly
higher risk for renal progression compared with their coun-
terparts (Fig. 2). A Cox proportional hazards regression
analysis revealed that 25(OH)D deficiency, is an independ-
ent risk factor for renal progression, after adjustment for
age, gender, systolic BP, proteinuria, eGFR, subsequent vita-
min D therapy, immunosuppressives treatment and ACEI/
ARB treatment [HR 5.99, 95 % confidence intervals (CIs)
1.59–22.54, P = 0.008] (Table 5). Moreover, as shown in
Fig. 3, the ROC curve was made comparing between
combined clinical score (eGFR + proteinuria) vs combined
clinical score + vitamin D level. It revealed that vitamin D
can add significant predictive information to the renal pro-
gression, manifested as a larger area under the ROC curves
(AUCs); the combined model (eGFR, proteinuria and vita-
min D score), 0.785; combined clinical score, 0.722.
Discussion
Results from this study display several relationships
between the plasma 25(OH)D level and several clinical
parameters related to the IgAN histological damage and
its severity. Our results also suggest that the plasma
25(OH)D level at the time of initial diagnosis may be an
independent inverse-predictor of IgAN progression.
Table 4 Plasma 25(OH)D level associated with tubular atrophy/
interstitial fibrosis in IgA nephropathy
Oxford score 25(OH)D level (ng/ml) P
M0 14.55 ± 8.70 0.142
M1 12.10 ± 7.72
E0 13.76 ± 8.50 0.443
E1 11.44 ± 4.19
S0 11.79 ± 8.22 0.198
S1 15.17 ± 8.33
T0 15.41 ± 8.89 0.008
T1 11.07 ± 6.80
T2 8.84 ± 4.75
Fig. 2 The patients with a deficiency of 25(OH)D are significantly associated with a higher risk for renal progression compared to those with a
higher level of 25(OH)D
Table 5 Risk factors for renal progression in multivariate Cox
regression analysis
HR (95 % CI) P value
Vitamin D deficiency 5.99 (1.59–22.54) 0.008
Male 1.87 (0.59–5.94) 0.287
eGFR 0.99 (0.97–1.01) 0.145
SBP 1.03 (1.00–1.05) 0.036
ALB 1.05 (0.99–1.12) 0.103
T0(reference) 1
T1-2 2.76 (0.68–11.24) 0.156
Proteinuria 1.14 (0.82–1.57) 0.432
ACEI angiotensin converting enzyme inhibitor, ARB angiotensin II receptor
blockade, eGFR estimated glomerularfiltration rate, SBP, systolic blood pressure,
ALB albumin
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Vitamin D deficiency or insufficiency is highly prevalent
among patients with CKD. An ethnically homogeneous
cohort by Ravani et al. showed that the prevalence of a
25(OH)D deficiency or insufficiency was increased from
25 % in stage 2 to 56 % in stage 5 [8]. Cumulative evidence
suggests an association of a low 25(OH)D level with clin-
ical parameters related to a kidney damage. For example,
Ravani et al. found that the baseline level of 25(OH)D was
directly and significantly correlated with eGFR [8]. Diniz
et al. also revealed an inverse correlation between the
25(OH)D level and proteinuria [30]. Furthermore, an in-
verse relationship between blood pressure and the
25(OH)D level has been documented as well in a number
of epidemiological studies [31, 32]. Our observations are
consistent with these previous reports.
Our observation of a more severe tubulointerstitial
damage in patients with a 25(OH)D deficiency is of inter-
est and suggests that a 25(OH)D deficiency in an early
stage of IgAN may point to an advanced renal injury.
Interstitial fibrosis together with tubular athrotrophy is a
hallmark of chronic renal failure and strongly correlates
with deterioration of renal function. Zhang Y. et al. [33]
have established vitamin D receptor-null mice that allow a
manipulation of unilateral ureteral obstruction for 7 days.
Compared with the wild-type mice, the VDR-null mice de-
velop more severe renal damage with marked tubular at-
rophy and interstitial fibrosis. Gonçalves et al. [34] found
recently that a 25(OH)D deficiency might potentiate tubu-
lointerstitial damages (fibrosis, inflammatory infiltration,
tubular dilation and atrophy) through those inflammatory
pathways that involve TGF-β1. Increased expression of
TGF-β1 and decreased expression of VDR and Klotho
protein are observed in VD deficient rats. The essential
role of TGF-β1 and the protective effect of Klotho protein
in pathogenesis of various renal diseases, including IgAN,
have been documented in different clinical and experi-
mental models [35–37].
There has been increasing evidence recommending the
plasma 25(OH)D level as a good indicator for deterior-
ation of renal function in various kidney diseases. In a pro-
spective study with a cohort of predialysis patients with
CKD, Nakano et al. [38] identified the serum 25(OH)D
concentration as a significant predictor of renal composite
outcome of doubling serum creatinine and ESRD. In the
same cohort, Hamano et al. [39] found a nonlinear associ-
ation between the serum 25(OH)D concentration and an-
nual decline in the renal function. A meta-analysis of
clinical observations reveals an inverse association be-
tween all-cause mortality and the serum 25(OH)D con-
centration [12], whereas our study shows that the
circulating 25(OH)D level determined at the time of diag-
nosis predicts the renal progression. This predictability is
not only independent of other important risk factors rele-
vant to renal progression in IgAN but is also unaffected
Fig. 3 An ROC curve analysis with various biomarkers for renal progression showing that the circulating level of 25(OH)D add significant
predictive information for patients’ renal progression
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by the treatment of vitamin D, RAS blockers or immuno-
suppresors. Given that tubulointerstitial damage is one of
the most important risk factors for renal progression in
IgAN, our findings that connect the renal histologic
features to the circulating level of 25(OH)D may partly
explain why a decreased 25(OH)D level predicts the
prognosis of IgAN.
In our study the follow-up period is too short to assess
the long-term renal outcomes such as ESRD, and death
in this patient population. Nevertheless, it is noteworthy
that this is the first study suggesting a prognostic value
of the circulating 25(OH)D in IgAN patients, although
its prognostic value for the much longer outcome still
awaits further study. Moreover, in the last decade obser-
vational studies have noted links between vitamin D de-
ficiency and poor cardiovascular outcomes in CKD
patients. Our study only demonstrated the reverse rela-
tionship of vitamin D and the blood pressure, but did
not test the relationship of 25(OH)D with other cardio-
vascular outcomes such as incident coronary heart dis-
ease and heart failure. Given the high-cardiovascular risk
of CKD, the issue deserves to be addressed in well pow-
ered future studies. Finally, our study did not address
the vitamin D treatment effect, thus an adequately pow-
ered randomized controlled trial should be designed to
determine whether 25 (OH) vitamin D therapy is able to
slow the progression of IgAN.
Conclusions
In conclusion, 25(OH)D deficiency is significantly corre-
lated with a poorer renal function and more severe renal
pathological features, and is strongly associated with in-
creased risk of renal progression in IgAN patients, mak-
ing a 25(OH)D deficiency a good prognostic marker to
predict the severity and clinical outcome in IgAN pa-
tients. Therefore, determining the circulating level of
25(OH)D may be important and informative for the
identification of high-risk patients and for the proper
management of IgAN.
Additional file
Additional file 1: A correlation analysis between serum phosphorus,
calcium, and PTH levels with vit D levels. 25(OH) positively related with
serum calcium and negatively related with serum phosphorus and PTH.
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